CLGN Relative Valuation
CLGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLGN is overvalued; if below, it's undervalued.
Historical Valuation
Collplant Biotechnologies Ltd (CLGN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 9.81. The fair price of Collplant Biotechnologies Ltd (CLGN) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.00
Fair
-19.09
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Collplant Biotechnologies Ltd. (CLGN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-5.85
EV/EBIT
Collplant Biotechnologies Ltd. (CLGN) has a current EV/EBIT of -5.85. The 5-year average EV/EBIT is 3.21. The thresholds are as follows: Strongly Undervalued below -44.24, Undervalued between -44.24 and -20.51, Fairly Valued between 26.93 and -20.51, Overvalued between 26.93 and 50.65, and Strongly Overvalued above 50.65. The current Forward EV/EBIT of -5.85 falls within the Historic Trend Line -Fairly Valued range.
1.78
PS
Collplant Biotechnologies Ltd. (CLGN) has a current PS of 1.78. The 5-year average PS is 55.63. The thresholds are as follows: Strongly Undervalued below -170.62, Undervalued between -170.62 and -57.49, Fairly Valued between 168.76 and -57.49, Overvalued between 168.76 and 281.88, and Strongly Overvalued above 281.88. The current Forward PS of 1.78 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Collplant Biotechnologies Ltd. (CLGN) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.21. The thresholds are as follows: Strongly Undervalued below -5.34, Undervalued between -5.34 and -3.27, Fairly Valued between 0.85 and -3.27, Overvalued between 0.85 and 2.91, and Strongly Overvalued above 2.91. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Collplant Biotechnologies Ltd. (CLGN) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.16. The thresholds are as follows: Strongly Undervalued below -5.13, Undervalued between -5.13 and -3.15, Fairly Valued between 0.82 and -3.15, Overvalued between 0.82 and 2.81, and Strongly Overvalued above 2.81. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Collplant Biotechnologies Ltd (CLGN) has a current Price-to-Book (P/B) ratio of 2.84. Compared to its 3-year average P/B ratio of 2.46 , the current P/B ratio is approximately 15.28% higher. Relative to its 5-year average P/B ratio of 3.72, the current P/B ratio is about -23.75% higher. Collplant Biotechnologies Ltd (CLGN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -21.22%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -14.65% , the current FCF yield is about -100.00% lower.
2.88
P/B
Median3y
2.46
Median5y
3.72
-37.93
FCF Yield
Median3y
-21.22
Median5y
-14.65
Competitors Valuation Multiple
The average P/S ratio for CLGN's competitors is 0.00, providing a benchmark for relative valuation. Collplant Biotechnologies Ltd Corp (CLGN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 1825.00%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CLGN decreased by 41.67% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 4.00K to 77.00K.
The secondary factor is the Margin Expansion, contributed -95.82%to the performance.
Overall, the performance of CLGN in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Collplant Biotechnologies Ltd (CLGN) currently overvalued or undervalued?
What is Collplant Biotechnologies Ltd (CLGN) fair value?
How does CLGN's valuation metrics compare to the industry average?
What is the current P/B ratio for Collplant Biotechnologies Ltd (CLGN) as of Dec 05 2025?
What is the current FCF Yield for Collplant Biotechnologies Ltd (CLGN) as of Dec 05 2025?
What is the current Forward P/E ratio for Collplant Biotechnologies Ltd (CLGN) as of Dec 05 2025?